

Table of Contents

Number	Title
1	Table 00: Comments
2	Table 01: Study population and enrolment information
3	Table 02: Patients by region, country, and cohort
4	Table 03 : Demographic Characteristics
5	Table 04 : Care setting , Type of AF and Insurance
6	Table 05 : Vital signs and life style
7	Table 06 : Clinical History
8	Table 07 : Treatment for stroke prophylaxis
9	Table 08: Treatment
10	Table 09 : Risk scores
11	Table 10: Treatment at baseline by CHA2DS2-VASc score
12	Table 11: Treatment at baseline by HAS-BLED score
13	Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4
14	Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4
15	Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4
16	Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4
17	Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
18	Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
19	Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4

Table 00: Comments

- 1 The data was extracted from the GARFIELD-AF registry database on 28 JUL 2016
- 2 The data includes retrospective patients in cohort 1 and prospective patients in cohort 1, 2, 3, 4 and 5
- 3 The variable 'Congestive heart failure' was split into 'History of CHF' and 'Current CHF' in cohorts 3, 4 and 5. History of and/or current CHF were used to identify CHF in cohort 3, 4 and 5 patients (Table 6)
- 4 The variable 'Coronary artery disease' was split into 'History of CAD' and 'Current CAD' in cohorts 3, 4 and 5. History of and/or current CAD were used to identify CAD in cohort 3, 4 and 5 patients (Table 6)
- 5 The variable 'Other thromboembolism' is not recorded for patients in cohort 3, 4 and 5
- 6 The option 'None' was added in the CRF for the 'Chronic renal disease' field in cohort 3, 4 and 5. The percentages for the variable 'Moderate to severe CKD' are estimated assuming that patients with 'unknown' stage of CKD are without 'Moderate to severe CKD' (Table 6)
- 7 Table 7 describes the baseline treatment for stroke prophylaxis. For each treatment group identifier options are mutually exclusive. The option 'unknown' includes combination of treatments
- 8 Table 8 shows the baseline treatment for stroke prophylaxis with non mutually exclusive groups
- 9 Table 12 shows INR values and TTR for patients treated with VKA±AP at baseline. INR readings during the first year of follow-up were included in the analysis. Values less than 0.8 or greater than 20 were removed since these values may not be plausible. Patients on VKA±AP at enrolment but with fewer than three readings during the follow-up were excluded from the analysis. Patient-level TTR was estimated by linear interpolation according to Rosendaal et al (1993), using 2.0-3.0 as the target INR range. TTR was estimated using INR readings until discontinuation or interruption of VKA or the end of follow-up. In addition, TTR was estimated between two consecutive INR readings only if the interval did not exceed 90 days.
- 10 Tables 13 and 14 describe events during the first year of follow-up for patients in cohorts 1-4. Only the first occurrence of each event was taken into account.
- 11 Table 13 Congestive heart failure during the follow-up includes new congestive heart failure or worsening of pre-existing congestive heart failure.

**Table 01: Study population and enrolment information
Full Analysis Dataset : GERMANY**

Number of prospective patients (C1+C2+C3+C4+C5)	3524
Number of enrolling sites	64
Number of enrolling countries	1
Enrolment period	23JUN2010 - 26JUL2016
Duration of enrolment (months)	73.1

**Table 02: Patients by region, country, and cohort
Full Analysis Dataset : GERMANY**

Region	Country	Cohort 1 Retrospective patients (N=799)	Cohort 1 Prospective patients (N=917)	Cohort 2 (N=917)	Cohort 3 (N=649)	Cohort 4 (N=517)	Cohort 5 (N=524)	Total Prospective patients Cohorts 1 to 5 (N=3524)	Total Prospective patients Cohorts 1 to 4 (N=3000)
Europe	Germany	799	917	917	649	517	524	3524	3000

**Table 03 : Demographic Characteristics
Full Analysis Dataset : GERMANY**

Variable	Statistics	Cohort 1 Retrospective patients (N=799) (n %)	Cohort 1 Prospective patients (N=917) (n %)	Cohort 2 (N=917) (n %)	Cohort 3 (N=649) (n %)	Cohort 4 (N=517) (n %)	Cohort 5 (N=524) (n %)	Total Prospective patients Cohorts 1 to 5 (N=3524)	Total Prospective patients Cohorts 1 to 4 (N=3000)
Sex, n(%)	n (missing)	799 (0)	917 (0)	917 (0)	649 (0)	517 (0)	524 (0)	3524 (0)	3000 (0)
	Male	446 (55.8)	496 (54.1)	492 (53.7)	310 (47.8)	297 (57.4)	277 (52.9)	1872 (53.1)	1595 (53.2)
	Female	353 (44.2)	421 (45.9)	425 (46.3)	339 (52.2)	220 (42.6)	247 (47.1)	1652 (46.9)	1405 (46.8)
Age at Diagnosis (Years)	n (missing)	799 (0)	917 (0)	917 (0)	649 (0)	517 (0)	524 (0)	3524 (0)	3000 (0)
	Mean (SD)	70.0 (10.4)	70.6 (11.0)	71.5 (10.9)	71.7 (11.4)	71.8 (10.7)	71.5 (11.1)	71.4 (11.0)	71.3 (11.0)
	Median (IQR)	71.0 (65.0 to 77.0)	72.0 (65.0 to 77.0)	73.0 (65.0 to 79.0)	74.0 (65.0 to 79.0)	74.0 (66.0 to 79.0)	74.0 (64.0 to 79.0)	73.0 (65.0 to 79.0)	73.0 (65.0 to 79.0)
	Min to Max	24 to 97	23 to 94	22 to 97	24 to 97	27 to 94	22 to 99	22 to 99	22 to 97
Age Group, n(%)	n (missing)	799 (0)	917 (0)	917 (0)	649 (0)	517 (0)	524 (0)	3524 (0)	3000 (0)
	<65	199 (24.9)	229 (25.0)	211 (23.0)	152 (23.4)	113 (21.9)	136 (26.0)	841 (23.9)	705 (23.5)
	65-74	316 (39.5)	330 (36.0)	307 (33.5)	203 (31.3)	164 (31.7)	148 (28.2)	1152 (32.7)	1004 (33.5)
	>=75	284 (35.5)	358 (39.0)	399 (43.5)	294 (45.3)	240 (46.4)	240 (45.8)	1531 (43.4)	1291 (43.0)
Time since AF Diagnosis (Weeks)	n (missing)	799 (0)	669 (248)	607 (310)	390 (259)	352 (165)	361 (163)	2379 (1145)	2018 (982)
	Mean (SD)	64.55 (24.90)	2.38 (1.78)	1.83 (1.61)	1.75 (1.59)	1.87 (1.67)	1.75 (1.56)	1.97 (1.68)	2.00 (1.69)
	Median (IQR)	64.10 (42.80 to 87.40)	2.00 (0.80 to 3.80)	1.20 (0.50 to 3.00)	1.10 (0.40 to 3.00)	1.20 (0.50 to 3.00)	1.10 (0.50 to 2.70)	1.40 (0.50 to 3.10)	1.40 (0.50 to 3.10)
	Min to Max	26.1 to 104.2	0.1 to 6.0	0.1 to 6.0	0.1 to 5.8	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0
Race, n(%)	n (missing)	784 (0)	895 (0)	917 (0)	642 (0)	513 (0)	508 (0)	3475 (0)	2967 (0)
	Caucasian	759 (96.8)	870 (97.2)	914 (99.7)	630 (98.1)	483 (94.2)	475 (93.5)	3372 (97.0)	2897 (97.6)
	Hispanic/Latino	2 (0.3)	-	2 (0.2)	3 (0.5)	-	-	5 (0.1)	5 (0.2)
	Afro-Caribbean	-	2 (0.2)	1 (0.1)	-	-	1 (0.2)	4 (0.1)	3 (0.1)

**Table 03 : Demographic Characteristics
Full Analysis Dataset : GERMANY**

Variable	Statistics	Cohort 1 Retrospective patients (N=799) (n %)	Cohort 1 Prospective patients (N=917) (n %)	Cohort 2 (N=917) (n %)	Cohort 3 (N=649) (n %)	Cohort 4 (N=517) (n %)	Cohort 5 (N=524) (n %)	Total Prospective patients Cohorts 1 to 5 (N=3524)	Total Prospective patients Cohorts 1 to 4 (N=3000)
	Asian (Not Chinese)	1 (0.1)	2 (0.2)	-	-	1 (0.2)	1 (0.2)	4 (0.1)	3 (0.1)
	Chinese	1 (0.1)	1 (0.1)	-	-	-	-	1 (0.0)	1 (0.0)
	Mixed/Other	21 (2.7)	20 (2.2)	-	9 (1.4)	29 (5.7)	31 (6.1)	89 (2.6)	58 (2.0)
	Unknown	15	22	-	7	4	16	49	33
Region, n(%)	n (missing)	799 (0)	917 (0)	917 (0)	649 (0)	517 (0)	524 (0)	3524 (0)	3000 (0)
	Europe	799 (100.0)	917 (100.0)	917 (100.0)	649 (100.0)	517 (100.0)	524 (100.0)	3524 (100.0)	3000 (100.0)

**Table 04 : Care setting , Type of AF and Insurance
Full Analysis Dataset : GERMANY**

Variable	Statistics	Cohort 1 Retrospective patients (N=799) (n %)	Cohort 1 Prospective patients (N=917) (n %)	Cohort 2 (N=917) (n %)	Cohort 3 (N=649) (n %)	Cohort 4 (N=517) (n %)	Cohort 5 (N=524) (n %)	Total Prospective patients Cohorts 1 to 5 (N=3524)	Total Prospective patients Cohorts 1 to 4 (N=3000)
Care Setting Speciality at Diagnosis, n(%)	n (missing)	799 (0)	916 (1)	917 (0)	649 (0)	517 (0)	524 (0)	3523 (1)	2999 (1)
	Internal Medicine	285 (35.7)	279 (30.5)	351 (38.3)	248 (38.2)	178 (34.4)	198 (37.8)	1254 (35.6)	1056 (35.2)
	Cardiology	225 (28.2)	330 (36.0)	290 (31.6)	181 (27.9)	162 (31.3)	165 (31.5)	1128 (32.0)	963 (32.1)
	Neurology	6 (0.8)	4 (0.4)	6 (0.7)	4 (0.6)	3 (0.6)	5 (1.0)	22 (0.6)	17 (0.6)
	Geriatrics	1 (0.1)	6 (0.7)	8 (0.9)	1 (0.2)	3 (0.6)	4 (0.8)	22 (0.6)	18 (0.6)
	Primary Care/General Practice	282 (35.3)	297 (32.4)	262 (28.6)	215 (33.1)	171 (33.1)	152 (29.0)	1097 (31.1)	945 (31.5)
Care Setting Location at Diagnosis, n(%)	n (missing)	794 (0)	916 (1)	917 (0)	649 (0)	517 (0)	524 (0)	3523 (1)	2999 (1)
	Hospital	267 (33.6)	309 (33.7)	380 (41.4)	225 (34.7)	155 (30.0)	173 (33.0)	1242 (35.3)	1069 (35.6)
	Office	494 (62.2)	562 (61.4)	467 (50.9)	381 (58.7)	350 (67.7)	330 (63.0)	2090 (59.3)	1760 (58.7)
	Anticoagulation clinic/thrombosi s centre	27 (3.4)	34 (3.7)	19 (2.1)	-	-	-	53 (1.5)	53 (1.8)
	Emergency room	6 (0.8)	11 (1.2)	51 (5.6)	43 (6.6)	12 (2.3)	21 (4.0)	138 (3.9)	117 (3.9)
	Unknown	5	-	-	-	-	-	-	-
Type of AF Diagnosed, n(%)	n (missing)	799 (0)	916 (1)	917 (0)	649 (0)	517 (0)	524 (0)	3523 (1)	2999 (1)
	Permanent	342 (42.8)	213 (23.3)	178 (19.4)	117 (18.0)	79 (15.3)	77 (14.7)	664 (18.8)	587 (19.6)
	Persistent	140 (17.5)	95 (10.4)	95 (10.4)	73 (11.2)	67 (13.0)	58 (11.1)	388 (11.0)	330 (11.0)
	Paroxysmal	221 (27.7)	220 (24.0)	185 (20.2)	166 (25.6)	124 (24.0)	162 (30.9)	857 (24.3)	695 (23.2)
	New	96 (12.0)	388 (42.4)	459 (50.1)	293 (45.1)	247 (47.8)	227 (43.3)	1614 (45.8)	1387 (46.2)

**Table 04 : Care setting , Type of AF and Insurance
Full Analysis Dataset : GERMANY**

Variable	Statistics	Cohort 1 Retrospective patients (N=799) (n %)	Cohort 1 Prospective patients (N=917) (n %)	Cohort 2 (N=917) (n %)	Cohort 3 (N=649) (n %)	Cohort 4 (N=517) (n %)	Cohort 5 (N=524) (n %)	Total Prospective patients Cohorts 1 to 5 (N=3524)	Total Prospective patients Cohorts 1 to 4 (N=3000)
Treatment Costs, n(%)	n (missing)	8 (0)	5 (0)	501 (0)	620 (0)	512 (0)	524 (0)	2162 (0)	1638 (0)
	Public insurance	5 (62.5)	5 (100.0)	472 (94.2)	590 (95.2)	477 (93.2)	500 (95.4)	2044 (94.5)	1544 (94.3)
	Private (insurance)	2 (25.0)	-	26 (5.2)	23 (3.7)	30 (5.9)	22 (4.2)	101 (4.7)	79 (4.8)
	Private (out of pocke	-	-	2 (0.4)	2 (0.3)	2 (0.4)	-	6 (0.3)	6 (0.4)
	Combination	1 (12.5)	-	1 (0.2)	5 (0.8)	3 (0.6)	2 (0.4)	11 (0.5)	9 (0.5)
	Unknown	791	912	416	29	5	-	1362	1362
Treatment Sector, n(%)	n (missing)	8 (0)	5 (0)	516 (0)	625 (0)	512 (0)	524 (0)	2182 (0)	1658 (0)
	In the public sector	7 (87.5)	5 (100.0)	467 (90.5)	603 (96.5)	483 (94.3)	509 (97.1)	2067 (94.7)	1558 (94.0)
	In the private sector	1 (12.5)	-	49 (9.5)	22 (3.5)	29 (5.7)	15 (2.9)	115 (5.3)	100 (6.0)
	Unknown	791	912	401	24	5	-	1342	1342

**Table 05 : Vital signs and life style
Full Analysis Dataset : GERMANY**

Variable	Statistics	Cohort 1 Retrospective patients (N=799) (n %)	Cohort 1 Prospective patients (N=917) (n %)	Cohort 2 (N=917) (n %)	Cohort 3 (N=649) (n %)	Cohort 4 (N=517) (n %)	Cohort 5 (N=524) (n %)	Total Prospective patients Cohorts 1 to 5 (N=3524)	Total Prospective patients Cohorts 1 to 4 (N=3000)
Height (cm)	n (missing)	757 (42)	872 (45)	819 (98)	586 (63)	483 (34)	451 (73)	3211 (313)	2760 (240)
	Mean (SD)	170.1 (9.6)	169.5 (9.4)	169.7 (9.3)	169.2 (9.9)	170.6 (9.2)	170.0 (9.6)	169.7 (9.5)	169.7 (9.5)
	Median (IQR)	170.0 (164.0 to 176.0)	169.0 (163.0 to 176.0)	170.0 (164.0 to 176.0)	169.0 (162.0 to 176.0)	170.0 (165.0 to 177.0)	170.0 (163.0 to 177.0)	170.0 (163.0 to 176.0)	170.0 (163.0 to 176.0)
	Min to Max	132 to 198	140 to 197	141 to 198	137 to 203	146 to 198	145 to 194	137 to 203	137 to 203
Weight (kg)	n (missing)	757 (42)	872 (45)	819 (98)	586 (63)	483 (34)	451 (73)	3211 (313)	2760 (240)
	Mean (SD)	83.3 (16.2)	83.3 (16.4)	84.3 (17.8)	84.2 (19.1)	84.4 (17.9)	84.2 (19.3)	84.0 (17.9)	84.0 (17.7)
	Median (IQR)	82.0 (72.0 to 92.0)	82.0 (72.5 to 94.0)	82.0 (72.0 to 93.0)	82.0 (71.0 to 95.0)	83.0 (73.0 to 95.0)	82.0 (71.0 to 95.0)	82.0 (72.0 to 94.0)	82.0 (72.0 to 94.0)
	Min to Max	36 to 148	35 to 160	45 to 154	42 to 190	43 to 200	37 to 183	35 to 200	35 to 200
BMI (kg/m ²)	n (missing)	757 (42)	872 (45)	819 (98)	586 (63)	483 (34)	451 (73)	3211 (313)	2760 (240)
	Mean (SD)	28.8 (4.9)	29.0 (5.1)	29.2 (5.4)	29.4 (5.9)	29.0 (5.7)	29.1 (6.1)	29.2 (5.6)	29.2 (5.5)
	Median (IQR)	28.0 (26.0 to 31.0)	28.0 (25.0 to 32.0)	28.0 (26.0 to 32.0)	28.0 (25.0 to 32.0)	28.0 (25.0 to 31.0)	28.0 (25.0 to 32.0)	28.0 (25.0 to 32.0)	28.0 (25.0 to 32.0)
	Min to Max	12 to 53	12 to 54	18 to 56	14 to 60	16 to 74	16 to 56	12 to 74	12 to 74
BMI Category, n(%)	n (missing)	757 (42)	872 (45)	819 (98)	586 (63)	483 (34)	451 (73)	3211 (313)	2760 (240)
	<19	3 (0.4)	13 (1.5)	1 (0.1)	3 (0.5)	7 (1.4)	6 (1.3)	30 (0.9)	24 (0.9)
	19-<25	144 (19.0)	182 (20.9)	167 (20.4)	130 (22.2)	92 (19.0)	99 (22.0)	670 (20.9)	571 (20.7)
	25-<30	350 (46.2)	334 (38.3)	340 (41.5)	217 (37.0)	220 (45.5)	188 (41.7)	1299 (40.5)	1111 (40.3)
	30-<40	239 (31.6)	322 (36.9)	276 (33.7)	205 (35.0)	147 (30.4)	134 (29.7)	1084 (33.8)	950 (34.4)
	>=40	21 (2.8)	21 (2.4)	35 (4.3)	31 (5.3)	17 (3.5)	24 (5.3)	128 (4.0)	104 (3.8)
Pulse (bpm)	n (missing)	651 (148)	809 (108)	840 (77)	589 (60)	485 (32)	476 (48)	3199 (325)	2723 (277)
	Mean (SD)	82.2 (22.2)	85.4 (24.3)	89.2 (26.0)	89.8 (26.0)	88.0 (24.1)	89.9 (25.5)	88.3 (25.2)	88.0 (25.2)
	Median (IQR)	76.0 (68.0 to 90.0)	80.0 (68.0 to 96.0)	84.0 (71.0 to 103.0)	84.0 (72.0 to 101.0)	84.0 (72.0 to 98.0)	84.0 (72.0 to 103.0)	82.0 (70.0 to 100.0)	82.0 (70.0 to 100.0)
	Min to Max	46 to 170	40 to 182	39 to 200	44 to 190	35 to 171	39 to 189	35 to 200	35 to 200

**Table 05 : Vital signs and life style
Full Analysis Dataset : GERMANY**

Variable	Statistics	Cohort 1 Retrospective patients (N=799) (n %)	Cohort 1 Prospective patients (N=917) (n %)	Cohort 2 (N=917) (n %)	Cohort 3 (N=649) (n %)	Cohort 4 (N=517) (n %)	Cohort 5 (N=524) (n %)	Total Prospective patients Cohorts 1 to 5 (N=3524)	Total Prospective patients Cohorts 1 to 4 (N=3000)
Systolic BP (mm Hg)	n (missing)	711 (88)	850 (67)	881 (36)	613 (36)	490 (27)	501 (23)	3335 (189)	2834 (166)
	Mean (SD)	137.7 (17.9)	137.7 (18.9)	138.6 (19.7)	136.9 (20.0)	136.7 (19.5)	137.3 (19.9)	137.6 (19.6)	137.6 (19.5)
	Median (IQR)	135.0 (128.0 to 150.0)	138.0 (125.0 to 150.0)	140.0 (130.0 to 150.0)	135.0 (125.0 to 150.0)	136.0 (124.0 to 150.0)	135.0 (124.0 to 150.0)	136.0 (125.0 to 150.0)	136.0 (125.0 to 150.0)
	Min to Max	80 to 210	85 to 250	80 to 242	94 to 240	90 to 217	86 to 238	80 to 250	80 to 250
Diastolic BP (mm Hg)	n (missing)	711 (88)	850 (67)	881 (36)	613 (36)	490 (27)	501 (23)	3335 (189)	2834 (166)
	Mean (SD)	82.1 (10.3)	81.5 (11.2)	81.6 (11.9)	80.8 (11.9)	80.2 (11.1)	82.2 (12.3)	81.3 (11.7)	81.2 (11.6)
	Median (IQR)	80.0 (75.0 to 90.0)	80.0 (75.0 to 90.0)	80.0 (75.0 to 90.0)	80.0 (74.0 to 86.0)	80.0 (74.0 to 85.0)	80.0 (75.0 to 90.0)	80.0 (75.0 to 90.0)	80.0 (75.0 to 90.0)
	Min to Max	55 to 125	50 to 140	45 to 132	46 to 140	50 to 131	45 to 140	45 to 140	45 to 140
LVEF (%)	n (missing)	391 (408)	481 (436)	430 (487)	299 (350)	221 (296)	217 (307)	1648 (1876)	1431 (1569)
	Mean (SD)	55.2 (11.2)	54.9 (11.6)	52.8 (12.8)	53.4 (12.6)	53.6 (12.1)	51.8 (13.8)	53.5 (12.5)	53.8 (12.3)
	Median (IQR)	58.0 (48.0 to 63.0)	55.0 (49.0 to 63.0)	55.0 (45.0 to 60.0)	55.0 (46.0 to 60.0)	55.0 (45.0 to 61.0)	55.0 (45.0 to 61.0)	55.0 (45.0 to 60.0)	55.0 (47.0 to 60.0)
	Min to Max	13 to 88	20 to 86	12 to 86	10 to 87	20 to 78	16 to 80	10 to 87	10 to 87
LVEF Category, n (missing) n(%)		391 (408)	481 (436)	430 (487)	299 (350)	221 (296)	217 (307)	1648 (1876)	1431 (1569)
	<40%	28 (7.2)	42 (8.7)	54 (12.6)	31 (10.4)	29 (13.1)	35 (16.1)	191 (11.6)	156 (10.9)
	>=40%	363 (92.8)	439 (91.3)	376 (87.4)	268 (89.6)	192 (86.9)	182 (83.9)	1457 (88.4)	1275 (89.1)
History of Hypertension, n(%)	n (missing)	799 (0)	916 (1)	917 (0)	647 (0)	517 (0)	521 (0)	3518 (1)	2997 (1)
	No	93 (11.6)	103 (11.2)	110 (12.0)	102 (15.8)	89 (17.2)	73 (14.0)	477 (13.6)	404 (13.5)
	Yes	706 (88.4)	813 (88.8)	807 (88.0)	545 (84.2)	428 (82.8)	448 (86.0)	3041 (86.4)	2593 (86.5)

**Table 05 : Vital signs and life style
Full Analysis Dataset : GERMANY**

Variable	Statistics	Cohort 1 Retrospective patients (N=799) (n %)	Cohort 1 Prospective patients (N=917) (n %)	Cohort 2 (N=917) (n %)	Cohort 3 (N=649) (n %)	Cohort 4 (N=517) (n %)	Cohort 5 (N=524) (n %)	Total Prospective patients Cohorts 1 to 5 (N=3524)	Total Prospective patients Cohorts 1 to 4 (N=3000)
	Unknown	-	-	-	2	-	3	5	2
Alcohol Consumption, n(%)	n (missing)	753 (0)	862 (1)	697 (0)	471 (0)	439 (0)	395 (0)	2864 (1)	2469 (1)
	Abstinent	323 (42.9)	369 (42.8)	217 (31.1)	199 (42.3)	196 (44.6)	168 (42.5)	1149 (40.1)	981 (39.7)
	Light	366 (48.6)	400 (46.4)	376 (53.9)	208 (44.2)	195 (44.4)	190 (48.1)	1369 (47.8)	1179 (47.8)
	Moderate	61 (8.1)	80 (9.3)	95 (13.6)	47 (10.0)	41 (9.3)	33 (8.4)	296 (10.3)	263 (10.7)
	Heavy	3 (0.4)	13 (1.5)	9 (1.3)	17 (3.6)	7 (1.6)	4 (1.0)	50 (1.7)	46 (1.9)
	Unknown	46	54	220	178	78	129	659	530
Smoker, n(%)	n (missing)	765 (0)	873 (1)	741 (0)	549 (0)	471 (0)	438 (0)	3072 (1)	2634 (1)
	No	552 (72.2)	610 (69.9)	507 (68.4)	394 (71.8)	340 (72.2)	324 (74.0)	2175 (70.8)	1851 (70.3)
	Ex-smoker	151 (19.7)	187 (21.4)	153 (20.6)	105 (19.1)	98 (20.8)	76 (17.4)	619 (20.1)	543 (20.6)
	Current smoker	62 (8.1)	76 (8.7)	81 (10.9)	50 (9.1)	33 (7.0)	38 (8.7)	278 (9.0)	240 (9.1)
	Unknown	34	43	176	100	46	86	451	365

Table 06 : Clinical History
Full Analysis Dataset : GERMANY

Variable	Statistics	Cohort 1 Retrospective patients (N=799) (n %)	Cohort 1 Prospective patients (N=917) (n %)	Cohort 2 (N=917) (n %)	Cohort 3 (N=649) (n %)	Cohort 4 (N=517) (n %)	Cohort 5 (N=524) (n %)	Total Prospective patients Cohorts 1 to 5 (N=3524)	Total Prospective patients Cohorts 1 to 4 (N=3000)
Congestive heart failure, n(%)	n (missing)	799 (0)	916 (1)	917 (0)	649 (0)	517 (0)	524 (0)	3523 (1)	2999 (1)
	No	623 (78.0)	692 (75.5)	697 (76.0)	552 (85.1)	459 (88.8)	458 (87.4)	2858 (81.1)	2400 (80.0)
	Yes	176 (22.0)	224 (24.5)	220 (24.0)	97 (14.9)	58 (11.2)	66 (12.6)	665 (18.9)	599 (20.0)
Congestive Heart Failure NYHA Class, n(%)	n (missing)	175 (623)	221 (693)	214 (697)	84 (552)	51 (459)	61 (458)	631 (2859)	570 (2401)
	I	29 (16.6)	39 (17.6)	36 (16.8)	8 (9.5)	3 (5.9)	5 (8.2)	91 (14.4)	86 (15.1)
	II	100 (57.1)	105 (47.5)	93 (43.5)	43 (51.2)	20 (39.2)	26 (42.6)	287 (45.5)	261 (45.8)
	III	41 (23.4)	70 (31.7)	74 (34.6)	30 (35.7)	26 (51.0)	27 (44.3)	227 (36.0)	200 (35.1)
	IV	5 (2.9)	7 (3.2)	11 (5.1)	3 (3.6)	2 (3.9)	3 (4.9)	26 (4.1)	23 (4.0)
	Unknown	1	3	6	13	7	5	34	29
Coronary artery disease, n(%)	n (missing)	799 (0)	916 (1)	917 (0)	649 (0)	517 (0)	524 (0)	3523 (1)	2999 (1)
	No	610 (76.3)	676 (73.8)	716 (78.1)	490 (75.5)	373 (72.1)	384 (73.3)	2639 (74.9)	2255 (75.2)
	Yes	189 (23.7)	240 (26.2)	201 (21.9)	159 (24.5)	144 (27.9)	140 (26.7)	884 (25.1)	744 (24.8)
Acute coronary syndrome, n(%)	n (missing)	799 (0)	916 (1)	917 (0)	643 (0)	513 (0)	520 (0)	3509 (1)	2989 (1)
	No	712 (89.1)	801 (87.4)	843 (91.9)	585 (91.0)	455 (88.7)	468 (90.0)	3152 (89.8)	2684 (89.8)
	Yes	87 (10.9)	115 (12.6)	74 (8.1)	58 (9.0)	58 (11.3)	52 (10.0)	357 (10.2)	305 (10.2)
	Unknown	-	-	-	6	4	4	14	10
Carotid Occlusive Disease, n(%)	n (missing)	799 (0)	916 (1)	916 (0)	640 (0)	512 (0)	499 (0)	3483 (1)	2984 (1)
	No	734 (91.9)	852 (93.0)	866 (94.5)	612 (95.6)	477 (93.2)	475 (95.2)	3282 (94.2)	2807 (94.1)

Table 06 : Clinical History
Full Analysis Dataset : GERMANY

Variable	Statistics	Cohort 1 Retrospective patients (N=799) (n %)	Cohort 1 Prospective patients (N=917) (n %)	Cohort 2 (N=917) (n %)	Cohort 3 (N=649) (n %)	Cohort 4 (N=517) (n %)	Cohort 5 (N=524) (n %)	Total Prospective patients Cohorts 1 to 5 (N=3524)	Total Prospective patients Cohorts 1 to 4 (N=3000)
	Yes	65 (8.1)	64 (7.0)	50 (5.5)	28 (4.4)	35 (6.8)	24 (4.8)	201 (5.8)	177 (5.9)
	Unknown	-	-	1	9	5	25	40	15
PE or DVT, n(%)	n (missing)	799 (0)	916 (1)	916 (0)	647 (0)	514 (0)	516 (0)	3509 (1)	2993 (1)
	No	765 (95.7)	877 (95.7)	873 (95.3)	624 (96.4)	501 (97.5)	497 (96.3)	3372 (96.1)	2875 (96.1)
	Yes	34 (4.3)	39 (4.3)	43 (4.7)	23 (3.6)	13 (2.5)	19 (3.7)	137 (3.9)	118 (3.9)
	Unknown	-	-	1	2	3	8	14	6
Other Thromboemboli sm, n(%)	n (missing)	799 (0)	916 (1)	911 (6)	0 (649)	0 (517)	0 (524)	1827 (1697)	1827 (1173)
	No	779 (97.5)	898 (98.0)	892 (97.9)	-	-	-	1790 (98.0)	1790 (98.0)
	Yes	20 (2.5)	18 (2.0)	19 (2.1)	-	-	-	37 (2.0)	37 (2.0)
Systemic Embolization, n(%)	n (missing)	799 (0)	916 (1)	916 (0)	647 (0)	513 (0)	515 (0)	3507 (1)	2992 (1)
	No	796 (99.6)	910 (99.3)	911 (99.5)	640 (98.9)	504 (98.2)	512 (99.4)	3477 (99.1)	2965 (99.1)
	Yes	3 (0.4)	6 (0.7)	5 (0.5)	7 (1.1)	9 (1.8)	3 (0.6)	30 (0.9)	27 (0.9)
	Unknown	-	-	1	2	4	9	16	7
Coronary Artery Bypass Graft, n(%)	n (missing)	656 (0)	750 (1)	916 (0)	648 (0)	516 (0)	523 (0)	3353 (1)	2830 (1)
	No	644 (98.2)	732 (97.6)	877 (95.7)	624 (96.3)	486 (94.2)	500 (95.6)	3219 (96.0)	2719 (96.1)
	Yes	12 (1.8)	18 (2.4)	39 (4.3)	24 (3.7)	30 (5.8)	23 (4.4)	134 (4.0)	111 (3.9)
	Unknown	143	166	1	1	1	1	170	169
Stroke/TIA, n(%)	n (missing)	799 (0)	916 (1)	917 (0)	649 (0)	517 (0)	524 (0)	3523 (1)	2999 (1)

Table 06 : Clinical History
Full Analysis Dataset : GERMANY

Variable	Statistics	Cohort 1 Retrospective patients (N=799) (n %)	Cohort 1 Prospective patients (N=917) (n %)	Cohort 2 (N=917) (n %)	Cohort 3 (N=649) (n %)	Cohort 4 (N=517) (n %)	Cohort 5 (N=524) (n %)	Total Prospective patients Cohorts 1 to 5 (N=3524)	Total Prospective patients Cohorts 1 to 4 (N=3000)
	No	666 (83.4)	787 (85.9)	807 (88.0)	576 (88.8)	445 (86.1)	468 (89.3)	3083 (87.5)	2615 (87.2)
	Yes	133 (16.6)	129 (14.1)	110 (12.0)	73 (11.2)	72 (13.9)	56 (10.7)	440 (12.5)	384 (12.8)
Stroke, n(%)	n (missing)	799 (0)	916 (1)	916 (0)	649 (0)	513 (0)	520 (0)	3514 (1)	2994 (1)
	No	723 (90.5)	847 (92.5)	855 (93.3)	613 (94.5)	475 (92.6)	496 (95.4)	3286 (93.5)	2790 (93.2)
	Yes	76 (9.5)	69 (7.5)	61 (6.7)	36 (5.5)	38 (7.4)	24 (4.6)	228 (6.5)	204 (6.8)
	Unknown	-	-	1	-	4	4	9	5
History of Bleeding, n(%)	n (missing)	799 (0)	916 (1)	916 (0)	649 (0)	515 (0)	518 (0)	3514 (1)	2996 (1)
	No	775 (97.0)	891 (97.3)	892 (97.4)	635 (97.8)	498 (96.7)	513 (99.0)	3429 (97.6)	2916 (97.3)
	Yes	24 (3.0)	25 (2.7)	24 (2.6)	14 (2.2)	17 (3.3)	5 (1.0)	85 (2.4)	80 (2.7)
	Unknown	-	-	1	-	2	6	9	3
Hypercholester olaemia, n(%)	n (missing)	799 (0)	916 (1)	916 (0)	630 (0)	493 (0)	493 (0)	3448 (1)	2955 (1)
	No	333 (41.7)	440 (48.0)	473 (51.6)	292 (46.3)	243 (49.3)	255 (51.7)	1703 (49.4)	1448 (49.0)
	Yes	466 (58.3)	476 (52.0)	443 (48.4)	338 (53.7)	250 (50.7)	238 (48.3)	1745 (50.6)	1507 (51.0)
	Unknown	-	-	1	19	24	31	75	44
Diabetes, n(%)	n (missing)	799 (0)	916 (1)	917 (0)	649 (0)	517 (0)	524 (0)	3523 (1)	2999 (1)
	No	580 (72.6)	651 (71.1)	656 (71.5)	461 (71.0)	371 (71.8)	385 (73.5)	2524 (71.6)	2139 (71.3)
	Type I	4 (0.5)	5 (0.5)	2 (0.2)	5 (0.8)	2 (0.4)	3 (0.6)	17 (0.5)	14 (0.5)
	Type II	215 (26.9)	260 (28.4)	259 (28.2)	183 (28.2)	144 (27.9)	136 (26.0)	982 (27.9)	846 (28.2)
Diabetes, n(%)	n (missing)	799 (0)	916 (1)	917 (0)	649 (0)	517 (0)	524 (0)	3523 (1)	2999 (1)
	No	580 (72.6)	651 (71.1)	656 (71.5)	461 (71.0)	371 (71.8)	385 (73.5)	2524 (71.6)	2139 (71.3)
	Yes	219 (27.4)	265 (28.9)	261 (28.5)	188 (29.0)	146 (28.2)	139 (26.5)	999 (28.4)	860 (28.7)
Cirrhosis, n(%)	n (missing)	799 (0)	916 (1)	916 (0)	624 (0)	498 (0)	505 (0)	3459 (1)	2954 (1)
	No	796 (99.6)	909 (99.2)	910 (99.3)	622 (99.7)	494 (99.2)	501 (99.2)	3436 (99.3)	2935 (99.4)

Table 06 : Clinical History
Full Analysis Dataset : GERMANY

Variable	Statistics	Cohort 1 Retrospective patients (N=799) (n %)	Cohort 1 Prospective patients (N=917) (n %)	Cohort 2 (N=917) (n %)	Cohort 3 (N=649) (n %)	Cohort 4 (N=517) (n %)	Cohort 5 (N=524) (n %)	Total Prospective patients Cohorts 1 to 5 (N=3524)	Total Prospective patients Cohorts 1 to 4 (N=3000)
	Yes	3 (0.4)	7 (0.8)	6 (0.7)	2 (0.3)	4 (0.8)	4 (0.8)	23 (0.7)	19 (0.6)
	Unknown	-	-	1	25	19	19	64	45
Dementia, n(%)	n (missing)	799 (0)	916 (1)	917 (0)	640 (0)	517 (0)	515 (0)	3505 (1)	2990 (1)
	No	777 (97.2)	882 (96.3)	885 (96.5)	623 (97.3)	509 (98.5)	503 (97.7)	3402 (97.1)	2899 (97.0)
	Yes	22 (2.8)	34 (3.7)	32 (3.5)	17 (2.7)	8 (1.5)	12 (2.3)	103 (2.9)	91 (3.0)
	Unknown	-	-	-	9	-	9	18	9
Hyperthyroidism, n(%)	n (missing)	799 (0)	916 (1)	917 (0)	643 (0)	512 (0)	517 (0)	3505 (1)	2988 (1)
	No	767 (96.0)	859 (93.8)	887 (96.7)	623 (96.9)	500 (97.7)	500 (96.7)	3369 (96.1)	2869 (96.0)
	Yes	32 (4.0)	57 (6.2)	30 (3.3)	20 (3.1)	12 (2.3)	17 (3.3)	136 (3.9)	119 (4.0)
	Unknown	-	-	-	6	5	7	18	11
Hypothyroidism, n(%)	n (missing)	799 (0)	916 (1)	917 (0)	644 (0)	512 (0)	518 (0)	3507 (1)	2989 (1)
	No	746 (93.4)	862 (94.1)	847 (92.4)	581 (90.2)	469 (91.6)	476 (91.9)	3235 (92.2)	2759 (92.3)
	Yes	53 (6.6)	54 (5.9)	70 (7.6)	63 (9.8)	43 (8.4)	42 (8.1)	272 (7.8)	230 (7.7)
	Unknown	-	-	-	5	5	6	16	10
Vascular Disease, n(%)	n (missing)	799 (0)	917 (0)	917 (0)	645 (4)	514 (3)	520 (4)	3513 (11)	2993 (7)
	No	662 (82.9)	743 (81.0)	781 (85.2)	539 (83.6)	420 (81.7)	430 (82.7)	2913 (82.9)	2483 (83.0)
	Yes	137 (17.1)	174 (19.0)	136 (14.8)	106 (16.4)	94 (18.3)	90 (17.3)	600 (17.1)	510 (17.0)
Moderate to Severe CKD, n(%)	n (missing)	799 (0)	916 (1)	917 (0)	649 (0)	517 (0)	524 (0)	3523 (1)	2999 (1)
	No	734 (91.9)	835 (91.2)	823 (89.7)	582 (89.7)	468 (90.5)	481 (91.8)	3189 (90.5)	2708 (90.3)
	Yes	65 (8.1)	81 (8.8)	94 (10.3)	67 (10.3)	49 (9.5)	43 (8.2)	334 (9.5)	291 (9.7)

Study ID: TRI08888

GARFIELD: International Registry of Patients Newly Diagnosed with AF

Table 06 : Clinical History
Full Analysis Dataset : GERMANY

**Table 07 : Treatment for stroke prophylaxis
Full Analysis Dataset : GERMANY**

Variable	Statistics	Cohort 1 Retrospective patients (N=799) (n %)	Cohort 1 Prospective patients (N=917) (n %)	Cohort 2 (N=917) (n %)	Cohort 3 (N=649) (n %)	Cohort 4 (N=517) (n %)	Cohort 5 (N=524) (n %)	Total Prospective patients Cohorts 1 to 5 (N=3524)	Total Prospective patients Cohorts 1 to 4 (N=3000)
Baseline Treatment, n(%)	n (missing)	769 (0)	877 (0)	913 (0)	643 (0)	513 (0)	521 (0)	3467 (0)	2946 (0)
	VKA	425 (55.3)	304 (34.7)	248 (27.2)	135 (21.0)	85 (16.6)	54 (10.4)	826 (23.8)	772 (26.2)
	VKA+AP	66 (8.6)	104 (11.9)	83 (9.1)	21 (3.3)	22 (4.3)	17 (3.3)	247 (7.1)	230 (7.8)
	FXA	11 (1.4)	28 (3.2)	86 (9.4)	218 (33.9)	227 (44.2)	302 (58.0)	861 (24.8)	559 (19.0)
	FXA+AP	9 (1.2)	19 (2.2)	41 (4.5)	53 (8.2)	54 (10.5)	28 (5.4)	195 (5.6)	167 (5.7)
	DTI	-	3 (0.3)	74 (8.1)	59 (9.2)	29 (5.7)	24 (4.6)	189 (5.5)	165 (5.6)
	DTI+AP	-	2 (0.2)	25 (2.7)	18 (2.8)	6 (1.2)	7 (1.3)	58 (1.7)	51 (1.7)
	AP	192 (25.0)	303 (34.5)	215 (23.5)	72 (11.2)	41 (8.0)	53 (10.2)	684 (19.7)	631 (21.4)
	NONE	66 (8.6)	114 (13.0)	141 (15.4)	67 (10.4)	49 (9.6)	36 (6.9)	407 (11.7)	371 (12.6)
	Unknown	30	40	4	6	4	3	57	54
	VKA±AP	491 (63.8)	408 (46.5)	331 (36.3)	156 (24.3)	107 (20.9)	71 (13.6)	1073 (30.9)	1002 (34.0)
	FXA±AP	20 (2.6)	47 (5.4)	127 (13.9)	271 (42.1)	281 (54.8)	330 (63.3)	1056 (30.5)	726 (24.6)
	DTI±AP	-	5 (0.6)	99 (10.8)	77 (12.0)	35 (6.8)	31 (6.0)	247 (7.1)	216 (7.3)
	FXA/DTI	11 (1.4)	31 (3.5)	160 (17.5)	277 (43.1)	256 (49.9)	326 (62.6)	1050 (30.3)	724 (24.6)
	FXA/DTI+AP	9 (1.2)	21 (2.4)	66 (7.2)	71 (11.0)	60 (11.7)	35 (6.7)	253 (7.3)	218 (7.4)
	FXA/DTI±AP	20 (2.6)	52 (5.9)	226 (24.8)	348 (54.1)	316 (61.6)	361 (69.3)	1303 (37.6)	942 (32.0)
	AC	436 (56.7)	335 (38.2)	408 (44.7)	412 (64.1)	341 (66.5)	380 (72.9)	1876 (54.1)	1496 (50.8)
	AC+AP	75 (9.8)	125 (14.3)	149 (16.3)	92 (14.3)	82 (16.0)	52 (10.0)	500 (14.4)	448 (15.2)
	AC±AP	511 (66.4)	460 (52.5)	557 (61.0)	504 (78.4)	423 (82.5)	432 (82.9)	2376 (68.5)	1944 (66.0)

Table 08: Treatment
Full Analysis Dataset : GERMANY

	Cohort 1 Retrospective (N=799) (n %)	Cohort 1 Prospective (N=917) (n %)	Cohort 2 (N=917) (n %)	Cohort 3 (N=649) (n %)	Cohort 4 (N=517) (n %)	Cohort 5 (N=524) (n %)	Total Prospective patients Cohorts 1 to 5 (N=3524)	Total Prospective patients Cohorts 1 to 4 (N=3000)
Anti-platelet (non mutually exclusive groups)								
Glycoprotein inhibitors	-	5 (0.5)	3 (0.3)	2 (0.3)	-	-	10 (0.3)	10 (0.3)
ADP receptor/P2Y12 inhibitors	38 (4.8)	68 (7.4)	48 (5.2)	21 (3.2)	25 (4.8)	23 (4.4)	185 (5.2)	162 (5.4)
Prostaglandin Cox inhibitors	1 (0.1)	-	-	-	-	-	-	-
ASA	131 (16.4)	154 (16.8)	2 (0.2)	35 (5.4)	9 (1.7)	9 (1.7)	209 (5.9)	200 (6.7)
	77 (9.6)	168 (18.3)	312 (34.0)	123 (19.0)	103 (19.9)	92 (17.6)	798 (22.6)	706 (23.5)
Anticoagulant drugs (non mutually exclusive groups)								
VKA	501 (62.7)	421 (45.9)	333 (36.3)	158 (24.3)	110 (21.3)	72 (13.7)	1094 (31.0)	1022 (34.1)
FXa	29 (3.6)	60 (6.5)	130 (14.2)	275 (42.4)	285 (55.1)	333 (63.5)	1083 (30.7)	750 (25.0)
DTI	1 (0.1)	5 (0.5)	100 (10.9)	79 (12.2)	36 (7.0)	33 (6.3)	253 (7.2)	220 (7.3)
Heparinoid	3 (0.4)	24 (2.6)	8 (0.9)	2 (0.3)	5 (1.0)	2 (0.4)	41 (1.2)	39 (1.3)
Heparins	20 (2.5)	33 (3.6)	174 (19.0)	74 (11.4)	27 (5.2)	21 (4.0)	329 (9.3)	308 (10.3)
Other	4 (0.5)	20 (2.2)	10 (1.1)	1 (0.2)	5 (1.0)	-	36 (1.0)	36 (1.2)

Table 09 : Risk scores
Full Analysis Dataset : GERMANY

Variable	Statistics	Cohort 1 Retrospective patients (N=799) (n %)	Cohort 1 Prospective patients (N=917) (n %)	Cohort 2 (N=917) (n %)	Cohort 3 (N=649) (n %)	Cohort 4 (N=517) (n %)	Cohort 5 (N=524) (n %)	Total Prospective patients Cohorts 1 to 5 (N=3524)	Total Prospective patients Cohorts 1 to 4 (N=3000)
CHADS2 Score	n (missing)	785 (14)	904 (13)	912 (5)	640 (9)	510 (7)	520 (4)	3486 (38)	2966 (34)
	Mean (SD)	2.1 (1.2)	2.1 (1.2)	2.1 (1.2)	2.0 (1.2)	2.0 (1.2)	2.0 (1.1)	2.1 (1.2)	2.1 (1.2)
	Median (IQR)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)
	Min to Max	0 to 6	0 to 6	0 to 6	0 to 6	0 to 6	0 to 6	0 to 6	0 to 6
CHADS2 score categories, n(%)	n (missing)	785 (14)	904 (13)	912 (5)	640 (9)	510 (7)	520 (4)	3486 (38)	2966 (34)
	0	22 (2.8)	34 (3.8)	38 (4.2)	41 (6.4)	27 (5.3)	27 (5.2)	167 (4.8)	140 (4.7)
	1	273 (34.8)	281 (31.1)	270 (29.6)	186 (29.1)	155 (30.4)	167 (32.1)	1059 (30.4)	892 (30.1)
	2	237 (30.2)	294 (32.5)	317 (34.8)	243 (38.0)	190 (37.3)	187 (36.0)	1231 (35.3)	1044 (35.2)
	3	146 (18.6)	181 (20.0)	171 (18.8)	103 (16.1)	83 (16.3)	96 (18.5)	634 (18.2)	538 (18.1)
	4	64 (8.2)	72 (8.0)	80 (8.8)	41 (6.4)	37 (7.3)	29 (5.6)	259 (7.4)	230 (7.8)
	5	35 (4.5)	29 (3.2)	28 (3.1)	22 (3.4)	15 (2.9)	13 (2.5)	107 (3.1)	94 (3.2)
	6	8 (1.0)	13 (1.4)	8 (0.9)	4 (0.6)	3 (0.6)	1 (0.2)	29 (0.8)	28 (0.9)
CHA2DS2- VASc Score	n (missing)	785 (14)	904 (13)	912 (5)	635 (14)	504 (13)	513 (11)	3468 (56)	2955 (45)
	Mean (SD)	3.5 (1.7)	3.6 (1.7)	3.6 (1.6)	3.5 (1.6)	3.5 (1.6)	3.4 (1.6)	3.5 (1.6)	3.5 (1.6)
	Median (IQR)	3.0 (2.0 to 5.0)	3.0 (2.0 to 5.0)	4.0 (2.0 to 5.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 5.0)	3.0 (2.0 to 5.0)
	Min to Max	0 to 8	0 to 9	0 to 8	0 to 8	0 to 9	0 to 8	0 to 9	0 to 9
CHA2DS2- VASc score categories, n(%)	n (missing)	785 (14)	904 (13)	912 (5)	635 (14)	504 (13)	513 (11)	3468 (56)	2955 (45)
	0	6 (0.8)	11 (1.2)	14 (1.5)	17 (2.7)	12 (2.4)	10 (1.9)	64 (1.8)	54 (1.8)
	1	70 (8.9)	88 (9.7)	87 (9.5)	45 (7.1)	39 (7.7)	53 (10.3)	312 (9.0)	259 (8.8)
	2	157 (20.0)	132 (14.6)	142 (15.6)	109 (17.2)	84 (16.7)	76 (14.8)	543 (15.7)	467 (15.8)
	3	183 (23.3)	228 (25.2)	209 (22.9)	149 (23.5)	121 (24.0)	136 (26.5)	843 (24.3)	707 (23.9)
	4	161 (20.5)	191 (21.1)	201 (22.0)	175 (27.6)	142 (28.2)	120 (23.4)	829 (23.9)	709 (24.0)

Table 09 : Risk scores
Full Analysis Dataset : GERMANY

Variable	Statistics	Cohort 1 Retrospective patients (N=799) (n %)	Cohort 1 Prospective patients (N=917) (n %)	Cohort 2 (N=917) (n %)	Cohort 3 (N=649) (n %)	Cohort 4 (N=517) (n %)	Cohort 5 (N=524) (n %)	Total Prospective patients Cohorts 1 to 5 (N=3524)	Total Prospective patients Cohorts 1 to 4 (N=3000)
	5	104 (13.2)	152 (16.8)	150 (16.4)	67 (10.6)	56 (11.1)	75 (14.6)	500 (14.4)	425 (14.4)
	6-9	104 (13.2)	102 (11.3)	109 (12.0)	73 (11.5)	50 (9.9)	43 (8.4)	377 (10.9)	334 (11.3)
HAS-BLED score	n (missing)	453 (346)	540 (377)	541 (376)	435 (214)	407 (110)	375 (149)	2298 (1226)	1923 (1077)
	Mean (SD)	1.5 (1.0)	1.6 (0.9)	1.5 (0.9)	1.4 (0.9)	1.4 (0.8)	1.3 (0.8)	1.4 (0.9)	1.5 (0.9)
	Median (IQR)	1.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)
	Min to Max	0 to 6	0 to 5	0 to 5	0 to 5	0 to 4	0 to 4	0 to 5	0 to 5
HAS-BLED score categories, n(%)	n (missing)	453 (346)	540 (377)	541 (376)	435 (214)	407 (110)	375 (149)	2298 (1226)	1923 (1077)
	0	61 (13.5)	43 (8.0)	72 (13.3)	52 (12.0)	52 (12.8)	66 (17.6)	285 (12.4)	219 (11.4)
	1	192 (42.4)	213 (39.4)	217 (40.1)	202 (46.4)	202 (49.6)	174 (46.4)	1008 (43.9)	834 (43.4)
	2	148 (32.7)	207 (38.3)	182 (33.6)	135 (31.0)	117 (28.7)	112 (29.9)	753 (32.8)	641 (33.3)
	3	39 (8.6)	62 (11.5)	60 (11.1)	40 (9.2)	30 (7.4)	20 (5.3)	212 (9.2)	192 (10.0)
	4	11 (2.4)	13 (2.4)	8 (1.5)	5 (1.1)	6 (1.5)	3 (0.8)	35 (1.5)	32 (1.7)
	5	1 (0.2)	2 (0.4)	2 (0.4)	1 (0.2)	-	-	5 (0.2)	5 (0.3)
	6-9	1 (0.2)	-	-	-	-	-	-	-

**Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : GERMANY**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Cohort 1 retrospective	0	2	40	-	-	-	-	-	-	-	-	-	-	1	20	2	40	1
	1	36	54.5	8	12.1	1	1.5	-	-	-	-	-	-	8	12.1	13	19.7	4
	2	77	51.3	11	7.3	1	0.7	2	1.3	-	-	-	-	41	27.3	18	12	7
	3	105	58.7	9	5	3	1.7	2	1.1	-	-	-	-	49	27.4	11	6.1	4
	4	102	65.4	14	9	2	1.3	1	0.6	-	-	-	-	31	19.9	6	3.8	5
	5	51	51.5	9	9.1	1	1	2	2	-	-	-	-	31	31.3	5	5.1	5
6-9	47	46.5	14	13.9	2	2	1	1	-	-	-	-	29	28.7	8	7.9	3	
Cohort 1 prospective	0	3	27.3	-	-	-	-	-	-	-	-	-	-	3	27.3	5	45.5	-
	1	24	28.9	9	10.8	2	2.4	1	1.2	-	-	-	-	29	34.9	18	21.7	5
	2	43	33.9	10	7.9	6	4.7	2	1.6	-	-	-	-	52	40.9	14	11	5
	3	80	36.9	25	11.5	7	3.2	2	0.9	-	-	-	-	60	27.6	43	19.8	11
	4	70	38.5	20	11	6	3.3	4	2.2	2	1.1	2	1.1	68	37.4	10	5.5	9
	5	52	35.1	25	16.9	6	4.1	8	5.4	1	0.7	-	-	43	29.1	13	8.8	4
6-9	28	28.9	14	14.4	1	1	1	1	-	-	-	-	44	45.4	9	9.3	5	
Cohort 2	0	1	7.1	-	-	3	21.4	-	-	1	7.1	-	-	3	21.4	6	42.9	-
	1	22	25.6	4	4.7	7	8.1	2	2.3	10	11.6	1	1.2	17	19.8	23	26.7	1
	2	42	29.6	7	4.9	18	12.7	4	2.8	13	9.2	2	1.4	33	23.2	23	16.2	-
	3	58	27.8	22	10.5	24	11.5	9	4.3	18	8.6	4	1.9	42	20.1	32	15.3	-
	4	55	27.6	16	8	16	8	16	8	15	7.5	10	5	40	20.1	31	15.6	2
	5	45	30	23	15.3	10	6.7	2	1.3	9	6	5	3.3	39	26	17	11.3	-
6-9	23	21.3	11	10.2	8	7.4	8	7.4	8	7.4	3	2.8	40	37	7	6.5	1	
Cohort 3	0	3	17.6	-	-	5	29.4	1	5.9	2	11.8	-	-	1	5.9	5	29.4	-
	1	4	8.9	-	-	20	44.4	3	6.7	2	4.4	-	-	7	15.6	9	20	-
	2	24	22.2	1	0.9	40	37	7	6.5	10	9.3	-	-	14	13	12	11.1	1
	3	36	24.5	6	4.1	46	31.3	9	6.1	17	11.6	4	2.7	16	10.9	13	8.8	2
4	38	22	8	4.6	61	35.3	13	7.5	17	9.8	6	3.5	17	9.8	13	7.5	2	

**Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : GERMANY**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
	5	11	16.4	2	3	21	31.3	6	9	5	7.5	4	6	10	14.9	8	11.9	-
	6-9	17	23.3	4	5.5	19	26	13	17.8	4	5.5	4	5.5	7	9.6	5	6.8	-
Cohort 4	0	1	8.3	-	-	4	33.3	2	16.7	-	-	-	-	1	8.3	4	33.3	-
	1	4	10.3	1	2.6	22	56.4	1	2.6	-	-	1	2.6	3	7.7	7	17.9	-
	2	13	15.5	2	2.4	37	44	8	9.5	7	8.3	1	1.2	8	9.5	8	9.5	-
	3	16	13.4	8	6.7	61	51.3	8	6.7	4	3.4	1	0.8	10	8.4	11	9.2	2
	4	32	22.9	6	4.3	54	38.6	23	16.4	5	3.6	-	-	10	7.1	10	7.1	2
	5	9	16.1	3	5.4	23	41.1	4	7.1	9	16.1	1	1.8	4	7.1	3	5.4	-
	6-9	7	14	2	4	21	42	7	14	3	6	2	4	5	10	3	6	-
Cohort 5	0	-	-	-	-	7	70	-	-	2	20	-	-	-	-	1	10	-
	1	3	5.7	1	1.9	35	66	1	1.9	4	7.5	-	-	2	3.8	7	13.2	-
	2	9	11.8	3	3.9	44	57.9	2	2.6	3	3.9	1	1.3	9	11.8	5	6.6	-
	3	16	11.9	1	0.7	72	53.7	8	6	6	4.5	4	3	17	12.7	10	7.5	2
	4	13	10.9	6	5	65	54.6	4	3.4	5	4.2	1	0.8	16	13.4	9	7.6	1
	5	7	9.3	4	5.3	48	64	3	4	3	4	1	1.3	6	8	3	4	-
	6-9	5	11.6	2	4.7	23	53.5	10	23.3	-	-	-	-	3	7	-	-	-
Total Prospective patients Cohorts 1 to 5	0	8	12.5	-	-	19	29.7	3	4.7	5	7.8	-	-	8	12.5	21	32.8	-
	1	57	18.6	15	4.9	86	28.1	8	2.6	16	5.2	2	0.7	58	19	64	20.9	6
	2	131	24.4	23	4.3	145	27	23	4.3	33	6.1	4	0.7	116	21.6	62	11.5	6
	3	206	24.9	62	7.5	210	25.4	36	4.4	45	5.4	13	1.6	145	17.6	109	13.2	17
	4	208	25.6	56	6.9	202	24.8	60	7.4	44	5.4	19	2.3	151	18.6	73	9	16
	5	124	25	57	11.5	108	21.8	23	4.6	27	5.4	11	2.2	102	20.6	44	8.9	4
	6-9	80	21.6	33	8.9	72	19.4	39	10.5	15	4	9	2.4	99	26.7	24	6.5	6

**Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : GERMANY**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	
Total	0	8	14.8	-	-	12	22.2	3	5.6	3	5.6	-	-	8	14.8	20	37	-	
Prospective patients																			
Cohorts 1 to 4																			
	1	54	21.3	14	5.5	51	20.2	7	2.8	12	4.7	2	0.8	56	22.1	57	22.5	6	
	2	122	26.5	20	4.3	101	21.9	21	4.6	30	6.5	3	0.7	107	23.2	57	12.4	6	
	3	190	27.5	61	8.8	138	19.9	28	4	39	5.6	9	1.3	128	18.5	99	14.3	15	
	4	195	28.1	50	7.2	137	19.7	56	8.1	39	5.6	18	2.6	135	19.5	64	9.2	15	
	5	117	27.8	53	12.6	60	14.3	20	4.8	24	5.7	10	2.4	96	22.8	41	9.7	4	
	6-9	75	22.9	31	9.5	49	14.9	29	8.8	15	4.6	9	2.7	96	29.3	24	7.3	6	

**Table 11: Treatment at baseline by HAS-BLED score
Full Analysis Dataset : GERMANY**

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	
Cohort 1 retrospective	0	48	82.8	-	-	-	-	-	-	-	-	-	-	-	-	-	10	17.2	3
	1	137	75.7	9	5	3	1.7	-	-	-	-	-	-	19	10.5	13	7.2	11	
	2	58	41.1	24	17	3	2.1	-	-	-	-	-	-	49	34.8	7	5	7	
	3	8	21.1	6	15.8	-	-	-	-	-	-	-	-	21	55.3	3	7.9	1	
	4-9	3	25	-	-	-	-	1	8.3	-	-	-	-	8	66.7	-	-	1	
Cohort 1 prospective	0	26	63.4	-	-	1	2.4	-	-	-	-	-	-	-	-	14	34.1	2	
	1	103	51.2	13	6.5	7	3.5	1	0.5	1	0.5	-	-	49	24.4	27	13.4	12	
	2	36	18.2	35	17.7	8	4	6	3	1	0.5	1	0.5	105	53	6	3	9	
	3	3	5	12	20	4	6.7	7	11.7	1	1.7	-	-	30	50	3	5	2	
	4-9	1	6.7	1	6.7	-	-	1	6.7	-	-	1	6.7	10	66.7	1	6.7	-	
Cohort 2	0	27	37.5	-	-	10	13.9	-	-	8	11.1	-	-	-	-	27	37.5	-	
	1	87	40.3	11	5.1	28	13	2	0.9	24	11.1	1	0.5	27	12.5	36	16.7	1	
	2	33	18.2	28	15.5	5	2.8	8	4.4	7	3.9	6	3.3	76	42	18	9.9	1	
	3	9	15	7	11.7	1	1.7	5	8.3	1	1.7	3	5	31	51.7	3	5	-	
	4-9	-	-	-	-	-	-	-	-	-	-	-	-	10	100	-	-	-	
Cohort 3	0	10	19.2	-	-	23	44.2	-	-	5	9.6	-	-	-	-	14	26.9	-	
	1	64	32.2	1	0.5	69	34.7	7	3.5	19	9.5	1	0.5	11	5.5	27	13.6	3	
	2	21	15.6	10	7.4	35	25.9	18	13.3	9	6.7	8	5.9	24	17.8	10	7.4	-	
	3	4	10.3	1	2.6	9	23.1	6	15.4	1	2.6	2	5.1	13	33.3	3	7.7	1	
	4-9	-	-	1	16.7	1	16.7	1	16.7	-	-	-	-	3	50	-	-	-	
Cohort 4	0	7	13.5	-	-	28	53.8	-	-	2	3.8	-	-	-	-	15	28.8	-	
	1	40	19.9	3	1.5	114	56.7	6	3	13	6.5	-	-	7	3.5	18	9	1	
	2	23	20	7	6.1	36	31.3	18	15.7	3	2.6	-	-	19	16.5	9	7.8	2	
	3	2	6.7	2	6.7	4	13.3	11	36.7	5	16.7	1	3.3	4	13.3	1	3.3	-	
	4-9	-	-	1	16.7	1	16.7	-	-	-	-	-	-	3	50	1	16.7	-	

**Table 11: Treatment at baseline by HAS-BLED score
Full Analysis Dataset : GERMANY**

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n		
Cohort 5	0	5	7.6	-	-	44	66.7	-	-	8	12.1	-	-	-	-	9	13.6	-
	1	22	12.7	2	1.2	113	65.3	1	0.6	7	4	6	3.5	9	5.2	13	7.5	1
	2	9	8.1	6	5.4	43	38.7	10	9	5	4.5	1	0.9	31	27.9	6	5.4	1
	3	-	-	3	15	4	20	6	30	2	10	-	-	5	25	-	-	-
	4-9	-	-	-	-	-	-	2	66.7	-	-	-	-	1	33.3	-	-	-
Total Prospective patients Cohorts 1 to 5	0	75	26.5	-	-	106	37.5	-	-	23	8.1	-	-	-	-	79	27.9	2
Total Prospective patients Cohorts 1 to 4	1	316	31.9	30	3	331	33.4	17	1.7	64	6.5	8	0.8	103	10.4	121	12.2	18
	2	122	16.5	86	11.6	127	17.2	60	8.1	25	3.4	16	2.2	255	34.5	49	6.6	13
	3	18	8.6	25	12	22	10.5	35	16.7	10	4.8	6	2.9	83	39.7	10	4.8	3
	4-9	1	2.5	3	7.5	2	5	4	10	-	-	1	2.5	27	67.5	2	5	-
	0	70	32.3	-	-	62	28.6	-	-	15	6.9	-	-	-	-	70	32.3	2
Total Prospective patients Cohorts 1 to 4	1	294	36	28	3.4	218	26.7	16	2	57	7	2	0.2	94	11.5	108	13.2	17
	2	113	18	80	12.7	84	13.4	50	7.9	20	3.2	15	2.4	224	35.6	43	6.8	12
	3	18	9.5	22	11.6	18	9.5	29	15.3	8	4.2	6	3.2	78	41.3	10	5.3	3
	4-9	1	2.7	3	8.1	2	5.4	2	5.4	-	-	1	2.7	26	70.3	2	5.4	-
	0	70	32.3	-	-	62	28.6	-	-	15	6.9	-	-	-	-	70	32.3	2

**Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : GERMANY**

Variable	Statistics	Cohort 1 Prospective patients (N=408) (n %)	Cohort 2 (N=331) (n %)	Cohort 3 (N=156) (n %)	Cohort 4 (N=107) (n %)	Total Prospective patients Cohorts 1 to 4 (N=1002)
TTR value, n(%)	n (missing)	242 (166)	208 (123)	98 (58)	68 (39)	616 (386)
	<65	145 (59.9)	125 (60.1)	55 (56.1)	47 (69.1)	372 (60.4)
	>=65	97 (40.1)	83 (39.9)	43 (43.9)	21 (30.9)	244 (39.6)
TTR	n (missing)	242 (166)	208 (123)	98 (58)	68 (39)	616 (386)
	Mean (SD)	56.6 (27.2)	54.0 (28.8)	60.4 (25.8)	50.0 (26.6)	55.6 (27.6)
	Median (IQR)	57.7 (38.0 to 77.5)	56.8 (32.9 to 76.5)	62.8 (39.6 to 80.2)	48.7 (30.7 to 69.5)	57.6 (35.4 to 77.5)
	Min to Max	0.0 to 100.0	0.0 to 100.0	0.0 to 100.0	0.0 to 100.0	0.0 to 100.0
INR value, n(%)	n	2868	2789	1338	934	7929
	2-3	1448 (50.5)	1410 (50.6)	726 (54.3)	446 (47.8)	4030 (50.8)
	<2	950 (33.1)	988 (35.4)	459 (34.3)	360 (38.5)	2757 (34.8)
	>3	470 (16.4)	391 (14.0)	153 (11.4)	128 (13.7)	1142 (14.4)
INR	n	2868	2789	1338	934	7929
	Mean (SD)	2.4 (0.8)	2.3 (0.8)	2.3 (0.8)	2.3 (0.8)	2.3 (0.8)
	Median (IQR)	2.2 (1.8 to 2.7)	2.2 (1.8 to 2.7)	2.2 (1.8 to 2.6)	2.1 (1.8 to 2.6)	2.2 (1.8 to 2.7)
	Min to Max	0.9 to 8.0	0.9 to 7.5	0.9 to 8.2	1.0 to 6.9	0.9 to 8.2

**Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : GERMANY**

Outcome	Cause	N	Events	Event rate /100 person-years	95% CI
All-cause death		3000	154	5.42	(4.63 to 6.35)
	Cardiovascular death	3000	68	2.40	(1.89 to 3.04)
	Non-Cardiovascular death	3000	59	2.08	(1.61 to 2.68)
	Undetermined cause	3000	27	0.95	(0.65 to 1.39)
Stroke/SE		3000	21	0.74	(0.48 to 1.14)
Major bleed		3000	18	0.64	(0.40 to 1.01)
Acute coronary syndrome		3000	31	1.09	(0.77 to 1.56)
Congestive Heart Failure		3000	94	3.37	(2.75 to 4.12)

**Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : GERMANY**

		GERMANY		
Outcome	Cause	N	Events	%
Cardiovascular causes	Myocardial infarction	68	6	8.82
	Ischaemic stroke	68	4	5.88
	Congestive heart failure	68	23	33.82
	Sudden or unwitnessed death	68	15	22.06
	Other	68	20	29.41
Non-cardiovascular causes	missing	59	1	1.70
	Respiratory failure	59	12	20.34
	Infection/sepsis	59	11	18.64
	Malignancy	59	11	18.64
	Other	59	24	40.68

**Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset :GERMANY**

OUTCOME	GERMANY		
	N	Events	%
Stroke(not including systemic embolism)	3000	16	0.53
Primary Ischemic Stroke	3000	9	0.30
Primary intracerebral hemorrhage*	3000	5	0.17
<i>Intracerebral</i>	3000	5	0.17
Undetermined	3000	2	0.07

*Note :Multiple choice question type that allows the respondent to choose one or multiple options from the list of possible answers.

**Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : GERMANY**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	54	51.00	1	1.96	(0.28 to 13.92)
1	259	251.55	2	0.80	(0.20 to 3.18)
2	467	453.00	6	1.33	(0.60 to 2.95)
3	707	668.06	33	4.94	(3.51 to 6.95)
4+	1468	1375.70	109	7.92	(6.57 to 9.56)
Unknown	45	40.01	3	7.50	(2.42 to 23.25)

**Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : GERMANY**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	54	50.95	1	1.96	(0.28 to 13.93)
1	259	251.55	0	-	-
2	467	451.38	3	0.67	(0.21 to 2.06)
3	707	666.12	4	0.60	(0.23 to 1.60)
4+	1468	1371.02	13	0.95	(0.55 to 1.63)
Unknown	45	40.01	0	-	-

**Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : GERMANY**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	54	51.00	0	-	-
1	259	251.55	0	-	-
2	467	451.40	2	0.44	(0.11 to 1.77)
3	707	665.57	4	0.60	(0.23 to 1.60)
4+	1468	1369.80	11	0.80	(0.45 to 1.45)
Unknown	45	39.67	1	2.52	(0.36 to 17.90)